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Abstract: Objective: To compare three different treatment protocols for Gardnerella vaginalis with respect to cure rates and secondary vulvovaginal candidiasis.

Turkish Health and Therapy Foundation, Ankara-Turkey

Methods: In this prospective randomised
study, initially 2285 patients with symptoms
of bacterial vaginosis were evaluated. Three
hundred and seven of them in whom Gardnerella vaginalis was recovered were eligible
for the study. Group I (114 patients) was
giver oral metronidazole 500mg twice daily
for one week; Group II (96 patients) was
prescribed oral metronidazole for one week
plus a vaginal suppository of Iyophilised lactobacilli, estriol and lactose for twelve days.
The third group (97 patients) was treated
only with the lactobacilli, estriol and lactose
suppositories for twelve days. If the patient
was relieved of her symptoms and Gardnerella vaginalis was not detected microbiologically at the second visit, it was considered as a cure. The treatment outcomes

Introduction
Bacterial vaginosis (BV) is a disturbance of the vaginal flora with overgrowth of anaerobic bacteria, Gardnerella vaginalis (GV) and is characterised by lack of
lactobacilli (1-3). It is well known that women are dependent on a normal vaginal flora which is dominated
by lactobacilli to maintain a healthy genital tract. The
primary mechanism of the dominance of the lactobacilli was thought to be related to the production of lactic acid and the acidic environment of the vagina. The
more recently described mechanisms are the generation of hydrogen peroxide by lactic acid bacteria, competition with other organisms for adherence to the
vaginal wall, production of protein inhibitors with antimicrobial properties and stimulation of the immune
system (4,5).
Oral metronidazole has been proven to be the
“gold standard” for the treatment of bacterial vaginosis (6). However, because of the side effects and the
potentialy teratogenic properties of metronidazole, oth-

were compared by Chi-sguare test and a p
value below 0.05 was considered as significant.
Results: The cure rate of Group III(55.6%)
was significantly lower than the cure rates of
Group I(87.7%)and II (92.7%) (p=0.0001).
Secondary vaginal candidiasis at the completion of the therapy was significantly lower in
the second (3.1%) and the third groups
(2.1%), while this rate was 12.2% for the
first group (p=003).
Conclusion: Metronidazole followed by lactobacilli, estriol and lactate suppositories
were found to be the best therapy model
with respect to cure and secondary candidiasis rates.

Key Words: Gardnerella vaginalis, vaginitis,
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er therapeutic measures have been studied. We conducted a randomised prospective clinical trial to compare the effects of three different treatment modalities (oral metronidazole, oral metronidazole plus
locally administered Iyophilised lactobacilli, and only locally administered Iyophilised lactobacilli) on the course
of bacterial vaginosis.
Methods
The study comprised the patients, from 18 to 53
years of age, who have visited the gynaecology clinic
from January 1994 to September 1995 for vaginal
symptoms. The vaginal symptoms at admittance were
itching or irritation in or around the vagina and a discharge of abnormal amount, odor or color. None of
the patients were pregnant and none of them had
signs of pelvic imflammatory disease. BV was diagnosed if any three of the following four criteria
were fulfilled (1): homogeneous discharge, pH greater
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than 4.5, clue cells in the wet mount and a positive
amine test. All specimens were processed within 2
hours. The cultures were plated on human bilayer
tween agar and after an incubation of 48 hours, the
plates were examined for colonies exhibiting diffuse
hemolysis (7). The following four criteria were also
evaluated for the diagnosis of GV: “clue cells”, gram
variable coccobacilli, absent or decreased lactobacilli
and a decrease in the leukocyte count of the vaginal
discharge. Only the patients who were diagnosed as
BV and whose cervicovaginal cultures revealed GV
were included in the study. The patients with Neisseria
gonorrhoea, Trichomonas vaginalis, Candida albicans
and Chlamydia trachomatis were excluded from the
study.
The patients were seen by three different gynecologists. Each gynecologist was assigned to one of
the treatment protocals. The patients were allocated
to one of the groups depending on which gynecologist
they have admitted at the beginning of the study. The
first group (Group I) was treated with oral metronidazole 500mg twice daily for one week. The second group (Group II) was prescribed the same treatment modality as the first group plus one vaginal
suppository each night for twelve days containing at
least 107 to 7x108 viable micro-organisms from a Iyophilised pure culture of Lactobacillus acidophilus,
600mg lactose and 0.03mg estriol in each suppository
(Gynoflor, Medinova AG, Zürich, Switzerland). The
third group (Group III) was given only one vaginal
suppository of lactobacilli, estriol and lactate each
night for twelve days.
The patiens were requested to come back after the
first mensturation following the completion of the
therapy (22-35 days after the admittance). The patients were re-evaluated with the same four criteria
and the same microbiologic methods. If the patient
was relieved of her symptoms and GV was not detected microbiologically at the second visit, it was considered as a cure. The ratio of secondary vulvovaginal
candidiasis was evaluated at the second visit and was
confirmed by the culture.
The treatment outcomes were compared by Chisquare test and a p value below 0.05 was considered
significant.
Results
From January 1994 to September 1995, 2285
women were evaluated for vaginal discharge and dis-
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comfort. Among them 307 patients were eligible for
the study. Group I comprised 114 patients, Group II
96 patients and Group III 97 patients. The three
groups were comparable in age, marital status, contraceptive use.
The cure rates were 87.7% (100 of 114) for
Group I, 92.7% (89 of 96) for Group II and 55.6%
(54 of 97) for Group III. The cure rate for Group I
and II are similar, but were significantly higher than
the third group (p=0.0001).
Serious or unexpected side effects were not noted.
None of the patients discontinued the treatment because of the side effects. A total number of 210 patients have received metronidazole and 2.4% have
complained from some degree of gastrointestinal discomfort. There was only one patient from the third
group who have complained about a burning sensation
of the vagina on the third day of the treatment, this
discomfort have ceased spontaneously while the patient
still continued the treatment.
Vulvovaginal candidiasis were found in 6.2% of the
patients at the second visit. The candidiasis rates for
Group II (3.1%) and Group III (2.1%) were significantly lower than the first group (12.2%)
(p=0.003).
Discussion
In this prospective study, three different treatment
protocols for bacterial vaginosis were investigated with
respect to the cure rates and secondary vulvovaginal
candidiasis. Our cure rates with metronidazole are
87.7% for Group I and 92.7% for Group II, which
are consistent with the literature (2,6,8,9). Hallen et
al. have reported a success rate of 57% with lactobacilli (10). Our figure (55.6%) is comparable with
theirs.
We have chosen Gynoflor, because it contains H2O2
producing viable lactobacilli, lactose and estriol.The aim
of adding lactose and estriol to the suppositories is to
provide the substrates to enhance the production of
H2O2.The uterine peroxidase activity is induced by estrogens (11,12). Another advantage of estriol is the
positive effect on epithelial growth with intensified
desquamation of epithelial cells and increased glycogen
supply for the preferential formation of the lactobacilli. With a dose of 0.03mg, estriol promotes the metabolic processes in the epithelium and provides a suitable environment for lactobacilli. Evidently a very small
amount of estriol is sufficient to saturate the highly
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specific estriol hormone receptors in the vagina that a
higher dosage does not produce any additional therapeutic effect and the amount absorbed is negligible.
The rate of secondary vulvovaginal candidiasis is
found to be low in the second and third groups when
lactobacilli suppositories were prescribed. Since BV is
found in the lack of lactobacilli, the suppositories
might have helped the vagina to gain its normal laclobacilli content and this might have prevented the
colonisation of other pathogen micro-organisms. It is
known from previous studies that the prevalence of C.
albicans is increased after metronidazole treatment
(13), Redondo-Lopez et al. have evaluated vulvovaginal
candidiasis complicating BV (14). In their study, multiple repetitive vaginal cultures identified Candida in
76% of the women with recurrent BV. Although the
exact mechanism for the high prevalence of candida infections in BV is obscure, it can be related to the failure to establish a lactobacilli-dominant flora in this
group of women.

In a study of Boecke et al. the effect of lactic acid
suppositories on BV was compared with metronidazole
and placebo. They found that lactic acid suppositories
were ineffective in BV, but in the lactic acid category
no vaginal Candida albicans infection was detected versus five in the metronidazole group and three in the
placebo group (15). These studies support our results.
In our study we have found with the addition of the
suppositories containing lactobacilli, estriol and lactate,
the cure rate of metronidazole has not changed, but
as a beneficial effect, the rate of the candida superinfection has decreased significantly.
Unfortunately because all of our patients were reevaluated only once, we do not know whether there is
a difference in the relapse rates after subsequent merstruations.
As a conclusion, we have found that metronidazole
followed by lactobacilli, estriol and lactate suppositories
is the best treatment modality with respect to the
cure rate and secondary vulvovaginal candidiasis rate.
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